Trial Profile
Single center, retrospective study evaluating prognostic ability of skeletal muscle density in ipilimumab treated malignant melanoma patients using computed tomography (CT) imaging.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Dec 2016
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 02 Dec 2016 New trial record
- 11 Oct 2016 Results of retrospective cutpoint analysis examining the prognostic ability of SMD in ipilimumab-treated MM patients presented at the 41st European Society for Medical Oncology Congress